Sana Biotechnology Inc. (SANA)
SANA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | SANA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001770121 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "There is substantial doubt as to our ability to continue as a going concern." | 10-Q 2026-11-05 |
| Cash and burn | $41.1M cash; operating cash flow -$35.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 299,634,951 (2026-10-29); 266,366,120 a year earlier; 197,133,208 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-04-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Seattle, Washington, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | $20.4M | -$38.8M | $41.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$63.6M | -$32.8M | $57.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$47.2M | -$37.4M | $83.8M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$58.8M | -$32.6M | $71.9M | No debt tags | Needs four quarters | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | Not filed | -$42.2M | -$29.4M | $103.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$93.8M | -$33.1M | $71.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$49.4M | -$48.7M | $96.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$49.1M | -$47.2M | $127.6M | No debt tags | Needs four quarters | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-13 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 392 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.8% |
| 1 month | -16.2% |
| 3 months | -45.0% |
| Year to date | -50.4% |
| 1 year | -44.8% |
| From 52-week high | -61.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IAM | Iambic Therapeutics Inc. | $11.85 | -9.54% | $561.7M |
| DNA | Ginkgo Bioworks Holdings Inc. | $8.50 | -11.55% | $551.0M |
| VALN | Valneva SE | $5.65 | -0.18% | $536.1M |
| ENTX | Entera Bio Ltd. | $3.02 | -2.89% | $525.9M |
| ETRA | Electra Therapeutics Inc. | $8.31 | -6.00% | $522.4M |
| SRZN | Surrozen Inc. | $32.32 | +2.25% | $616.1M |
| CGEM | Cullinan Therapeutics Inc. | $9.50 | -7.59% | $616.7M |
| FDMT | 4D Molecular Therapeutics Inc. | $11.29 | -7.69% | $636.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier